Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 11, 2023

BUY
$1.12 - $1.49 $60,592 - $80,609
54,100 Added 25.75%
264,176 $314,000
Q1 2023

Apr 28, 2023

BUY
$1.19 - $2.19 $79 - $146
67 Added 0.03%
210,076 $315,000
Q4 2022

Feb 13, 2023

SELL
$1.07 - $1.34 $47,615 - $59,630
-44,500 Reduced 17.48%
210,009 $254,000
Q3 2022

Nov 01, 2022

SELL
$1.09 - $1.67 $936 - $1,434
-859 Reduced 0.34%
254,509 $277,000
Q2 2022

Aug 02, 2022

BUY
$1.13 - $3.69 $59,437 - $194,094
52,600 Added 25.94%
255,368 $380,000
Q1 2022

Apr 27, 2022

BUY
$2.85 - $3.73 $79,666 - $104,264
27,953 Added 15.99%
202,768 $666,000
Q4 2021

Jan 24, 2022

BUY
$3.24 - $5.18 $17,982 - $28,749
5,550 Added 3.28%
174,815 $589,000
Q3 2021

Oct 21, 2021

BUY
$3.94 - $5.84 $60,479 - $89,644
15,350 Added 9.97%
169,265 $863,000
Q2 2021

Jul 29, 2021

BUY
$4.26 - $6.5 $21,300 - $32,500
5,000 Added 3.36%
153,915 $676,000
Q1 2021

May 13, 2021

BUY
$5.03 - $8.8 $47,030 - $82,280
9,350 Added 6.7%
148,915 $924,000
Q4 2020

Jan 22, 2021

SELL
$4.04 - $5.31 $106,045 - $139,382
-26,249 Reduced 15.83%
139,565 $683,000
Q3 2020

Oct 14, 2020

BUY
$3.64 - $7.76 $118,409 - $252,432
32,530 Added 24.41%
165,814 $697,000
Q2 2020

Aug 06, 2020

BUY
$4.78 - $8.26 $270,820 - $467,986
56,657 Added 73.94%
133,284 $925,000
Q1 2020

Apr 30, 2020

BUY
$4.0 - $21.53 $109,000 - $586,692
27,250 Added 55.19%
76,627 $306,000
Q4 2019

Feb 14, 2020

BUY
$13.94 - $24.12 $147,764 - $255,672
10,600 Added 27.34%
49,377 $1.06 Million
Q3 2019

Nov 08, 2019

BUY
$13.89 - $23.16 $73,950 - $123,303
5,324 Added 15.91%
38,777 $587,000
Q2 2019

Aug 06, 2019

BUY
$16.27 - $20.51 $544,280 - $686,121
33,453 New
33,453 $649,000

Others Institutions Holding AMRN

About AMARIN CORP PLCUK


  • Ticker AMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 403,206,016
  • Market Cap $222M
  • Description
  • Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for r...
More about AMRN
Track This Portfolio

Track Avantax Advisory Services, Inc. Portfolio

Follow Avantax Advisory Services, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Avantax Advisory Services, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Avantax Advisory Services, Inc. with notifications on news.